Articles tagged with Cancer Patients
Researchers have developed a new DNA microarray technology that can measure the unique genetic changes in breast cancer patients. This technology has the potential to identify new biomarkers for various types of cancer and serve as a universal cancer biomarker.
A new study found that the active ingredient in cannabis can help cancer patients regain their appetites and sense of taste. The study showed that THC-treated patients reported an increased appreciation of food, better quality of sleep, and relaxation compared to those receiving placebo.
A blood test can accurately detect biomolecular markers of bladder cancer risk linked to environmental exposures like cigarette smoke and industrial pollutants. The test measures methylation patterns in immune system cells, which are associated with an increased likelihood of disease.
A study found that women with melanoma report higher levels of both positive and negative impacts of cancer, including increased worries about UV radiation. Women also adjust their sun behavior more often and experience difficulties in getting life insurance as a result of their diagnosis.
The American Cancer Society has received a Presidential Citation Award from the American Academy of Hospice and Palliative Medicine for its efforts in promoting palliative care for patients with cancer. The organization has funded over $7 million in research grants to improve quality of life for patients, survivors, and their families.
The commentary highlights knowledge gaps in current guidelines for cancer survivors, emphasizing the need for longer-term research to address chronic health conditions. Nutrition interventions are seen as crucial in preventing cancer recurrence and managing comorbidities.
A new balloon kyphoplasty procedure provides rapid pain relief, increased mobility, and reduced need for painkillers compared to standard non-surgical care. Cancer patients with spinal fractures experience improved spinal function, quality of life, and pain during the study period.
A small proportion of adult cancer patients participate in clinical trials due to low physician referrals. Medical and radiation oncologists were more likely to refer patients, as well as those in larger practices and academic appointments.
Scientists at Queen's University Belfast have discovered the role of an enzyme that causes life-threatening damage to the heart when cancer patients receive chemotherapy, restricting treatment doses. New drugs targeting this enzyme could reduce heart damage and increase survival rates.
A new study found a link between low-dose ionizing radiation exposure from cardiac imaging and therapeutic procedures and an increased risk of incident cancer. Patients who underwent more procedures were more likely to develop cancer, particularly in the abdomen and chest areas.
Researchers propose cancer cells employ ancient genetic pathways, a 'toolkit' from 1 billion years ago, to evade control and develop resistance. This concept offers new hope for personalized medicine and potentially reveals clues about life's history.
A new FDA-approved drug, Sodium Fluoride F18, has been approved for use in bone scans, providing a safer alternative to the radioactive tracer Technetium-99m. The drug offers improved images using PET imaging, enabling better and earlier detection of bone metastases in cancer patients.
A recent study by Beth Israel Deaconess Medical Center researchers found that nonprofit hospice agencies disproportionately care for patients with diagnoses associated with less skilled care and longer lengths of stay. This may lead to financial obstacles in providing appropriate care for the neediest patients.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
Yosef Shiloh, a renowned expert in ataxia-telangiectasia (A-T) research, has been awarded the 51st Annual AACR G.H.A. Clowes Memorial Award for his groundbreaking work on cellular DNA damage response and A-T. His discoveries have significantly advanced our understanding of this rare genomic instability syndrome.
A novel form of personalized therapy using genetically engineered anti-tumor immune cells shows promising results in treating metastatic melanoma and synovial cell sarcoma. The technique, called adoptive immunotherapy, resulted in response rates of 45% and 67% in malignant melanoma and synovial cell sarcoma patients, respectively.
A study from Henry Ford Hospital found that photodynamic therapy can preserve vocal cord function in patients with early-stage laryngeal cancer. The treatment, which uses a powerful laser and light-activated drug, showed consistent trends toward normal vocal cord vibration over several weeks and months.
Researchers identified a gene signature that can accurately assess which breast cancer patients are at risk of relapse. The test has the potential to identify low-risk patients who may not require aggressive treatments, balancing risks against benefits.
A new gene test can identify which bladder cancer patients may have cancer spread in their lymph nodes, allowing doctors to determine the best course of treatment. The test analyzes 20 genes on tumor biopsies and has shown promising results in a large sample of patients.
Researchers discovered that IDH mutation leads to a metabolic battle between molecules ?-KG and 2-HG, contributing to cancer development. Bolstering ?-KG production could offer a new treatment option for patients with the mutation, which affects 75% of people with low-grade brain tumors and 20% of those with acute myeloid leukemia.
The Khalifa bin Zayed Al Nahyan Charity Foundation is granting $150 million to support genetic-analysis based research, diagnosis and treatment of cancer at the University of Texas M. D. Anderson Cancer Center.
Thea Friedman, oncology basic research director at the John Theurer Cancer Center, has received a $2 million NIH grant to advance blood and marrow transplant research. Her team aims to develop personalized transplantation techniques using T cell receptor analysis to separate donor cells responsible for graft-versus-host disease from th...
A meta-analysis found depression affects approximately one-sixth of cancer patients, with about a third having more widely defined mood disorder. The study suggests that depression is not an inevitable consequence of cancer diagnosis.
A recent U-M study reveals that cancer survivors are likely to experience pain at some point in their care, with 43% of racially diverse survivors experiencing pain since diagnosis. The study also found that women and blacks are more prone to chronic pain and disability due to pain.
A study found that preoperative Breast MRI detected occult cancer in nearly 1 in 8 patients, resulting in an added cancer yield of 12%. The use of preoperative Breast MRI is a relatively new indication for the test, with benefits seen in detecting otherwise hidden additional disease.
A new three-drug regimen including docetaxel has been shown to significantly improve the long-term survival of patients with locally advanced head and neck cancer. The addition of docetaxel to a standard two-drug chemotherapy regimen reduced the likelihood of death by 26% over six years, according to results from the TAX 324 trial.
Researchers at Mayo Clinic report significant improvements in fertility preservation techniques, including egg freezing and embryo storage. The advancements provide new options for young cancer patients seeking to conceive after treatment.
Researchers found that people with higher levels of folate in their red blood cells were more likely to have two tumor-suppressing genes shut down by methylation. Folate supplementation may lead to increased DNA methylation, potentially increasing the risk of diseases including cancer and other aging-related conditions.
A study of 61 adults found that 86.9% of parents with a genetic mutation supporting melanoma testing in their children cited increased risk awareness as a reason. Participants believed genetic testing could lead to improved prevention and screening behavior, such as reduced sun exposure and protective clothing use.
A recent study published in Pain found that cancer patients who smoke experience greater pain than nonsmokers, with increased pain severity and interference with daily activities. Quitting smoking may reduce pain over time, suggesting a potential benefit for cancer patients.
Patients with oral squamous cell carcinoma who experience early or lymph node recurrence after initial treatment tend to have poorer outcomes. The study suggests that local recurrences within six months are associated with worse survival rates, while regional recurrences at longer intervals also negatively impact survival.
Researchers at the University of Gothenburg have confirmed that ovarian cancer tissue and healthy tissue smell different, using an electronic nose. The discovery has major practical implications for early detection and treatment of ovarian cancer.
A study of 184 patients with advanced head and neck cancers found that 85% could speak normally and 63% could swallow normally after treatment. Factors such as age, smoking history, tumor location, and planned surgery were linked to poorer speech and swallowing outcomes.
A combination therapy of entinostat and erlotinib showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC) and elevated E-cadherin levels. The treatment was more effective than using erlotinib alone, leading to a large improvement in survival for patients with high E-cadherin expression.
A study found that transvaginal ultrasound screening can detect endometrial cancer in asymptomatic postmenopausal women with good sensitivity and specificity. The optimal cutoff for endometrial thickness was 5.15mm, detecting 80.5% of cancer cases
A new study by researchers at MD Anderson Cancer Center found that metastatic breast cancer patients with circulating tumor cells (CTCs) before or after treatment have shorter survival periods. Patients with higher percentages of epithelial cells or specific cellular transitions had higher chances for relapse. The study suggests that u...
Researchers have found a two-drug combination to be safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients with additional diseases or poor performance status. The combination of 5-azacitidine and vorinostat has shown promising results, with 83% survival rate after 60 days.
A phase II study at Georgetown University Medical Center suggests exemestane reduces mammographic breast density in high-risk postmenopausal women by 7%. The treatment is considered an intermediate marker for breast cancer and may offer a safer alternative to tamoxifen, which has rare but serious side effects.
Alexander V. Prokhorov, a behavioral scientist at the University of Texas MD Anderson Cancer Center, has been recognized for his innovative tobacco research and education programs targeting high-risk teens and young adults. His work includes developing video games and websites to teach healthy lifestyles and prevent tobacco use.
A new three-drug combination, CRd, has shown promising results in treating newly diagnosed blood cancer patients, including a high response rate and minimal side effects. The study found that all participants responded to treatment and achieved significant reductions in disease.
A clinical trial testing RG7112 has shown clinical activity and effectiveness in some patients with leukemia, including one patient in complete remission. The study suggests a potential new way to fight certain types of cancer with fewer side effects.
A new study suggests that using fecal immunochemical testing between colonoscopies can detect colorectal cancer and advanced tumors in high-risk patients. The test detected 12 out of 14 cancers and 60 out of 96 advanced adenomas, reducing the chance of finding cancer or advanced adenoma by 50%.
The John Theurer Cancer Center has showcased research advancements in lymphoma, multiple myeloma, stem cell transplantation, and leukemia. A study found that early autologous peripheral blood stem cell transplantation improved overall survival for patients with newly diagnosed multiple myeloma.
A study published in The Lancet found that daily low-dose aspirin reduced death rates from a range of common cancers by 21% during trials. Long-term follow-up showed that the risk of cancer death remained 20-60% lower in groups who had previously been allocated aspirin.
A study found that exposure to death and dying can help palliative care professionals develop a better understanding of life's meaning, become more spiritual, and come to terms with their own mortality. The study challenges widely held misconceptions about the inherently morbid nature of caring for the dying.
Researchers found that apixaban was more effective than enoxaparin in preventing major venous thromboembolism without increasing bleeding risk. This innovative treatment has improved methods for patients undergoing hip or knee replacement surgery, and may also be beneficial for cancer patients with VTE.
Researchers plan an international project to analyze cancer-related proteins, enabling tailored treatments. The initiative could lead to improved treatment outcomes within 5 years of completion.
A recent study suggests that radiation exposure from CT scans is lower than previously estimated, with cancer incidences related to ionizing radiation found to be 0.02% and 0.04% in two groups.
The John Theurer Cancer Center will unveil 40 cutting-edge studies at the 52nd ASH Annual Meeting, featuring research on lymphoma, multiple myeloma, and blood disorders. Six investigators were first authors of 13 studies, solidifying their leadership role in cancer treatment.
Research suggests that most women with small HER2-positive breast cancers could benefit from trastuzumab treatment due to the favorable prognosis and low risk of recurrence. The authors recommend discussing the benefits and risks of adjuvant trastuzumab with patients.
Cancer treatment decisions will be based on biology as medical oncologists need skills and knowledge to implement personalized medicine. Governments, companies, and clinicians must adapt drug development with targeted patient selection, shorter trials, and cost-effectiveness improvements.
Scientists have discovered a previously undiscovered trigger mechanism that monitors the structure of the cell's nucleus and delays cell division if it's not correct. This discovery may shed light on how cancer starts and could lead to new research into cancer prevention.
A new study found that black children are more likely to have the high-risk form of neuroblastoma and show signs of resistance to modern treatment. The study also showed disparities in outcome according to race, with black patients having a lower survival rate than white patients.
A recent study published in Cancer found that clinical stage does not predict recurrence risk for patients with localized prostate cancer after having their prostate removed. Despite frequent errors in assigning stage, there was no association between clinical stage and prostate cancer recurrence.
A study found that using true whole-body field view in PET/CT imaging can lead to more accurate staging and restaging of cancer patients. This increased accuracy can result in changes to treatment plans and the selection of biopsy sites, ultimately reducing unnecessary invasive procedures.
A multidisciplinary clinic approach to treating aggressive prostate cancer has been shown to improve survival rates and reduce distress among patients. The study, conducted over 15 years at the Kimmel Cancer Center, found that a team of specialists working together can provide more effective treatment options and better patient outcomes.
A new study found significant changes in targeted genes in patients' tumors, suggesting existing therapies may benefit more cancer patients. The research identified potential targets for treatment with existing targeted therapies.
A three-year study analyzing primary care data aims to establish clearer guidelines for doctors on preventing venous thromboembolism (VTE) in cancer patients. Researchers believe that targeted preventative treatments could prevent up to 3,000 deaths annually.
Researchers found that administering arsenic trioxide after initial standard treatment improved survival rates for patients with acute promyelocytic leukemia (APL). The study, which involved 481 patients, showed significant benefits in event-free survival and overall survival.
Researchers discovered a key mutation in the DNA methyltransferase 3A gene that affects AML treatment prognosis, leading to significantly shorter survival times for patients with the mutation. The study's findings suggest that treating patients with this mutation aggressively may improve their outcomes.